TG Therapeutics Inc (NASDAQ: TGTX) kicked off on Monday, down -2.00% from the previous trading day, before settling in for the closing price of $24.46. Over the past 52 weeks, TGTX has traded in a range of $6.46-$25.38.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 2506.46% over the past five years. While this was happening, its average annual earnings per share was recorded -43.06%. With a float of $137.95 million, this company’s outstanding shares have now reached $151.42 million.
Let’s look at the performance matrix of the company that is accounted for 264 employees. In terms of profitability, gross margin is 92.69%, operating margin of 29.37%, and the pretax margin is 27.62%.
TG Therapeutics Inc (TGTX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of TG Therapeutics Inc is 10.90%, while institutional ownership is 59.29%. The most recent insider transaction that took place on Jun 20 ’24, was worth 275,791. In this transaction Director of this company sold 16,348 shares at a rate of $16.87, taking the stock ownership to the 105,195 shares. Before that another transaction happened on Jun 17 ’24, when Company’s Director sold 9,585 for $16.39, making the entire transaction worth $157,098. This insider now owns 99,293 shares in total.
TG Therapeutics Inc (TGTX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -43.06% per share during the next fiscal year.
TG Therapeutics Inc (NASDAQ: TGTX) Trading Performance Indicators
Take a look at TG Therapeutics Inc’s (TGTX) current performance indicators. Last quarter, stock had a quick ratio of 2.83. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.70. Likewise, its price to free cash flow for the trailing twelve months is 54.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.60, a number that is poised to hit 0.02 in the next quarter and is forecasted to reach 0.75 in one year’s time.
Technical Analysis of TG Therapeutics Inc (TGTX)
TG Therapeutics Inc (NASDAQ: TGTX) saw its 5-day average volume 2.6 million, a negative change from its year-to-date volume of 3.67 million. As of the previous 9 days, the stock’s Stochastic %D was 78.31%. Additionally, its Average True Range was 1.29.
During the past 100 days, TG Therapeutics Inc’s (TGTX) raw stochastic average was set at 88.67%, which indicates a significant increase from 76.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.69% in the past 14 days, which was higher than the 60.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.18, while its 200-day Moving Average is $16.65. Nevertheless, the first resistance level for the watch stands at $24.60 in the near term. At $25.22, the stock is likely to face the second major resistance level. The third major resistance level sits at $25.80. If the price goes on to break the first support level at $23.40, it is likely to go to the next support level at $22.82. Assuming the price breaks the second support level, the third support level stands at $22.20.
TG Therapeutics Inc (NASDAQ: TGTX) Key Stats
The company with the Market Capitalisation of 3.71 billion has total of 154,543K Shares Outstanding. Its annual sales at the moment are 233,660 K in contrast with the sum of 12,670 K annual income. Company’s last quarter sales were recorded 73,470 K and last quarter income was 6,880 K.
